These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3481358)

  • 1. Ofloxacin for prevention of bacterial infections in granulocytopenic patients.
    Kern W; Kurrle E; Vanek E
    Infection; 1987; 15(6):427-33. PubMed ID: 3481358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.
    Kern W; Kurrle E
    Infection; 1991; 19(2):73-80. PubMed ID: 2050424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
    Winston DJ; Ho WG; Bruckner DA; Gale RP; Champlin RE
    Am J Med; 1990 Jan; 88(1):36-42. PubMed ID: 2153006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-bacterial effect of ofloxacin--in vitro and in vivo results].
    Altay G; Tulunay C
    Mikrobiyol Bul; 1985 Oct; 19(4):183-9. PubMed ID: 3868736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
    D'Antonio D; Piccolomini R; Iacone A; Fioritoni G; Parruti G; Betti S; Quaglietta AM; Accorsi P; Dell'Isola M; Favalli C
    J Antimicrob Chemother; 1994 Apr; 33(4):837-44. PubMed ID: 8056702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone infections: treatment by ofloxacin. Apropos of 10 cases].
    Bernard E; Etesse H; Garraffo R; Giaume F; Dellamonica P
    Pathol Biol (Paris); 1987 May; 35(5):644-7. PubMed ID: 3302877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients.
    Rubinstein E; Mark Z; Keren G; Alkan M; Berger S; Bogokowski B
    Infection; 1986; 14 Suppl 1():S20-5. PubMed ID: 3514469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit.
    Verwaest C; Verhaegen J; Ferdinande P; Schetz M; Van den Berghe G; Verbist L; Lauwers P
    Crit Care Med; 1997 Jan; 25(1):63-71. PubMed ID: 8989178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the sensitivity of bacteria of various origin to ofloxacin.
    Gubina M
    Chemioterapia; 1987 Apr; 6(2):79-81. PubMed ID: 3474082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.
    Rozenberg-Arska M; Dekker AW; Verhoef J
    J Infect Dis; 1985 Jul; 152(1):104-7. PubMed ID: 3159811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activity of ofloxacin and its mode of action.
    Sato K; Inoue Y; Fujii T; Aoyama H; Mitsuhashi S
    Infection; 1986; 14 Suppl 4():S226-30. PubMed ID: 3028966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of bacterial infections in granulocytopenic patients.
    Henry SA
    Am J Med; 1984 Apr; 76(4):645-51. PubMed ID: 6369979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofloxacin therapy of difficult-to-treat infections due to multiresistant organisms.
    el-Baz W; Osman L; Abd-el-Hamid T; el-Bokl M; Sabbour MS
    Chemioterapia; 1987 Apr; 6(2):129-33. PubMed ID: 3474079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin.
    Dennig D; Fülle HH; Hellriegel KP
    Onkologie; 1987 Feb; 10(1):57-8. PubMed ID: 3295628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients.
    de Vries-Hospers HG; Sleijfer DT; Mulder NH; van der Waaij D; Neiweg HO; van Saene HK
    Antimicrob Agents Chemother; 1981 May; 19(5):813-20. PubMed ID: 7027923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of ofloxacin versus trimethoprim-sulfamethoxazole on the aerobic flora in granulocytopenic subjects.
    Bartoloni A; Fanci R; Orsi A; Aquilini D; Bosi A; Rossi Ferrini P; Paradisi F
    J Chemother; 1989 Apr; 1(2):91-4. PubMed ID: 2732784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract.
    Sleijfer DT; Mulder NH; de Vries-Hospers HG; Fidler V; Nieweg HO; van der Waaij D; van Saene HK
    Eur J Cancer (1965); 1980 Jun; 16(6):859-69. PubMed ID: 6997054
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ofloxacin in the conservative therapy of acute and chronic otitis media--a preliminary clinical report of experiences].
    Lenarz T
    Infection; 1986; 14 Suppl 1():S87-8. PubMed ID: 3456987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients.
    Bow EJ; Louie TJ; Riben PD; McNaughton RD; Harding GK; Ronald AR
    Am J Med; 1984 Feb; 76(2):223-33. PubMed ID: 6364804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofloxacin treatment in the management of chronic osteitis.
    Ketterl R; Beckurts T; Stübinger B; Claudi B
    Drugs; 1987; 34 Suppl 1():124-30. PubMed ID: 3481313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.